NCT02520115View on ClinicalTrials.gov

Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

September 30, 2018

Study Completion Date

November 30, 2018

Conditions
Adnexal MassBorderline Ovarian Epithelial TumorOvarian Clear Cell TumorOvarian Endometrioid TumorOvarian NeoplasmOvarian Serous TumorRecurrent Ovarian Carcinoma
Interventions
DRUG

Dexamethasone

Given PO

OTHER

Laboratory Biomarker Analysis

Analysis of serum and tissue samples

DRUG

Valproic Acid

Given PO

Trial Locations (2)

48201

Wayne State University/Karmanos Cancer Institute, Detroit

48706

Karmanos Cancer Institute at McLaren Bay Region, Bay City, Bay City

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT02520115 - Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer | Biotech Hunter | Biotech Hunter